Published: June 2011

M² Medicines Monitoring: Launch of a new Scheme

Prescriber Update 32(2): 18
June 2011

A new medicines monitoring scheme, M², has been launched to promote reporting of adverse reactions to specific medicines of interest.

Stimulating reporting of specific reactions to specific medicines helps CARM and Medsafe to investigate possible safety signals further, decide if there is a causal relationship, and take action if necessary.

M² has been developed in collaboration with the MARC and CARM. Further information about the scheme can be found on the Medsafe website at:

An evaluation of the safety signal at the conclusion of the monitoring period will be published on the Medsafe website. The medicines and reactions that are being monitored are listed below.

M² logo


Please send your reports for these potential safety issues* listed in the table below.

Medicine Potential safety issue Active monitoring period ends*
Rivaroxaban Atrial fibrillation 1 September 2011
Simvastatin Joint pain and swelling 1 September 2011
Quetiapine Cardiomyopathy 1 September 2011
  • M² logo is a Medsafe scheme designed to collect more information on potential safety signals for specific medicines.
  • Safety signals are identified from reports of adverse medicine reactions sent to the Centre for Adverse Reactions Monitoring (CARM). For further information see the Medsafe website.
  • The M² logo scheme does not replace routine adverse reaction reporting. Find out how to report at: or

CARM logo - connecting you to New Zealand central & local government services

Medsafe logo

*The appearance of a possible safety issue in this scheme does not mean Medsafe and CARM have concluded that this medicine causes the reaction.